2026-06-14T03:42:03Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/181212024-09-21T19:36:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16983

00925njm 22002777a 4500 dc Bullón-Vela, Vanessa author Abete, Itziar author Zulet, Maria Angeles author Xu, Yifan author Martínez-González, Miguel A author Sayón-Orea, Carmen author Ruiz-Canela, Miguel author Toledo, Estefanía author Sánchez, Vicente Martín author Estruch, Ramon author Lamuela-Raventós, Rosa María author Almanza-Aguilera, Enrique author Fitó, Montserrat author Salas-Salvadó, Jordi author Díaz-López, Andrés author Tinahones, Francisco J author Tur, Josep A author Romaguera, Dora author Konieczna, Jadwiga author Pintó, Xavier author Daimiel, Lidia author Rodriguez-Mateos, Ana author Alfredo Martínez, José author 2020-09-22 Metabolic syndrome (MetS) components are strongly associated with increased risk of non-alcoholic fatty liver disease (NAFLD) development. Several studies have supported that resveratrol is associated with anti-inflammatory and antioxidant effects on health status. The main objective of this study was to assess the putative associations between some urinary resveratrol phase II metabolites, cardiometabolic, and liver markers in individuals diagnosed with MetS. In this cross-sectional study, 266 participants from PREDIMED Plus study (PREvención con DIeta MEDiterránea) were divided into tertiles of total urinary resveratrol phase II metabolites (sum of five resveratrol conjugation metabolites). Urinary resveratrol metabolites were analyzed by ultra- performance liquid chromatography coupled to triple quadrupole mass spectrometry (UPLC-Q-q-Q MS), followed by micro-solid phase extraction (µ-SPE) method. Liver function markers were assessed using serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Moreover, lipid profile was measured by triglycerides, very-low-density lipoprotein cholesterol (VLDL-c), and total cholesterol/high-density lipoprotein ratio (total cholesterol/HDL). Linear regression adjusted models showed that participants with higher total urine resveratrol concentrations exhibited improved lipid and liver markers compared to the lowest tertile. For lipid determinations: log triglycerides (βT3= -0.15, 95% CI; -0.28, -0.02, p-trend = 0.030), VLDL-c, (βT3= -4.21, 95% CI; -7.97, -0.46, p-trend = 0.039), total cholesterol/HDL ratio Moreover, (βT3= -0.35, 95% CI; -0.66, -0.03, p-trend = 0.241). For liver enzymes: log AST (βT3= -0.12, 95% CI; -0.22, -0.02, p-trend = 0.011, and log GGT (βT3= -0.24, 95% CI; -0.42, -0.06, p-trend = 0.002). However, there is no difference found on glucose variables between groups. To investigate the risk of elevated serum liver markers, flexible regression models indicated that total urine resveratrol metabolites were associated with a lower risk of higher ALT (169.2 to 1314.3 nmol/g creatinine), AST (599.9 to 893.8 nmol/g creatinine), and GGT levels (169.2 to 893.8 nmol/g creatinine). These results suggested that higher urinary concentrations of some resveratrol metabolites might be associated with better lipid profile and hepatic serum enzymes. Moreover, urinary resveratrol excreted showed a reduced odds ratio for higher liver enzymes, which are linked to NAFLD. 10.3390/molecules25184340 1420-3049 Molecules (Basel, Switzerland) http://hdl.handle.net/10668/16308 http://hdl.handle.net/20.500.13003/9509 32971870 L632982128 2-s2.0-85091622844 http://hdl.handle.net/20.500.12105/18121 580769100001 Antioxidant Inflammation Liver enzymes Metabolic syndrome Non-alcoholic fatty liver disease Resveratrol Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome